Piper Sandler Maintains Overweight on Biomarin Pharmaceutical, Maintains $107 Price Target
Portfolio Pulse from Benzinga Newsdesk
Piper Sandler analyst Christopher Raymond has reiterated an Overweight rating on Biomarin Pharmaceutical (NASDAQ:BMRN) with a maintained price target of $107.
August 27, 2024 | 3:28 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Piper Sandler has reiterated its Overweight rating on Biomarin Pharmaceutical, maintaining a price target of $107. This suggests confidence in the company's stock performance.
The reaffirmation of an Overweight rating and a $107 price target by Piper Sandler indicates a positive outlook on Biomarin's stock. This can lead to increased investor confidence and potential upward movement in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100